Sigi Kay

895 total citations
30 papers, 592 citations indexed

About

Sigi Kay is a scholar working on Genetics, Immunology and Hematology. According to data from OpenAlex, Sigi Kay has authored 30 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 12 papers in Immunology and 11 papers in Hematology. Recurrent topics in Sigi Kay's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and CAR-T cell therapy research (6 papers). Sigi Kay is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and CAR-T cell therapy research (6 papers). Sigi Kay collaborates with scholars based in Israel, United States and France. Sigi Kay's co-authors include Chava Perry, Varda Deutsch, Yair Herishanu, Aaron Polliack, Elizabeth Naparstek, Irit Avivi, Ben‐Zion Katz, Nili Dezorella, Marjorie Pick and Ron Ram and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Sigi Kay

28 papers receiving 585 citations

Peers

Sigi Kay
Kamruz Darabi United States
Oscar Muñoz United States
Roelof Flierman Netherlands
Luis Gerardo Rodríguez‐Lobato Spain
Kazuhiro Mochizuki Japan
Zsofia Bittner Germany
Maria Velegraki Greece
Roseanna Hargreaves United Kingdom
Rita I Azevedo Portugal
Rafael Andreu Spain
Kamruz Darabi United States
Sigi Kay
Citations per year, relative to Sigi Kay Sigi Kay (= 1×) peers Kamruz Darabi

Countries citing papers authored by Sigi Kay

Since Specialization
Citations

This map shows the geographic impact of Sigi Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sigi Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sigi Kay more than expected).

Fields of papers citing papers by Sigi Kay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sigi Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sigi Kay. The network helps show where Sigi Kay may publish in the future.

Co-authorship network of co-authors of Sigi Kay

This figure shows the co-authorship network connecting the top 25 collaborators of Sigi Kay. A scholar is included among the top collaborators of Sigi Kay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sigi Kay. Sigi Kay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horn, Galit, Anat Globerson Levin, Sigi Kay, et al.. (2023). The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy. Cancers. 15(23). 5611–5611. 4 indexed citations
2.
Ben‐Ezra, Jonathan, et al.. (2023). Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes – A potential prognostic marker?. Frontiers in Oncology. 12. 988998–988998.
3.
Ram, Ron, Tal Freund, Tami Halperin, et al.. (2022). Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study. Transplantation and Cellular Therapy. 28(5). 278.e1–278.e4. 7 indexed citations
4.
5.
Ram, Ron, David Hagin, Tal Freund, et al.. (2021). Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study. Transplantation and Cellular Therapy. 27(9). 788–794. 94 indexed citations
6.
Luttwak, Efrat, David Hagin, Chava Perry, et al.. (2020). Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series. Bone Marrow Transplantation. 56(5). 1031–1037. 27 indexed citations
7.
Tomer, Aaron, et al.. (2019). Pathogenic heparin‐induced thrombocytopenia and thrombosis (HIT) antibodies determined by rapid functional flow cytometry. European Journal Of Haematology. 103(3). 225–233. 7 indexed citations
8.
9.
Herishanu, Yair, Ben‐Zion Katz, Nili Dezorella, et al.. (2017). Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. Haematologica. 102(5). 874–882. 72 indexed citations
10.
Katz, Ben‐Zion, Chava Perry, Clare Sun, et al.. (2016). Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia. Blood. 128(22). 2018–2018. 1 indexed citations
11.
Herishanu, Yair, Sigi Kay, Erel Joffe, et al.. (2014). Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. Leukemia Research. 38(4). 484–489. 5 indexed citations
12.
Herishanu, Yair, Sigi Kay, Nadav Sarid, et al.. (2013). Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. Leukemia Research. 37(10). 1222–1228. 17 indexed citations
13.
Perry, Chava, et al.. (2013). Endurance Exercise Diverts the Balance between Th17 Cells and Regulatory T Cells. PLoS ONE. 8(10). e74722–e74722. 40 indexed citations
14.
Sobotta, Mirko C., Lev Shvidel, A Berrébi, et al.. (2013). CD84 is a survival receptor for CLL cells. Oncogene. 33(8). 1006–1016. 33 indexed citations
15.
Herishanu, Yair, Jonathan Ben‐Ezra, Ninette Amariglio, et al.. (2012). Complete Spontaneous Regression of Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 30(26). e254–e256. 3 indexed citations
16.
Kay, Sigi, et al.. (2011). Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos. British Journal of Cancer. 105(11). 1708–1718. 5 indexed citations
17.
Deutsch, Varda, Sigi Kay, Ben‐Zion Katz, et al.. (2010). Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte‐progenitor cells from cord blood. British Journal of Haematology. 149(1). 137–149. 12 indexed citations
18.
Dezorella, Nili, Meirav Pevsner‐Fischer, Varda Deutsch, et al.. (2009). Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Experimental Cell Research. 315(11). 1904–1913. 24 indexed citations
19.
Tavor, Sigal, Jasmine Jacob‐Hirsch, Talia Golan, et al.. (2008). The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia. 22(12). 2151–2158. 85 indexed citations
20.
Kay, Sigi, Yair Herishanu, Marjorie Pick, et al.. (2006). Quantitative flow cytometry of ZAP‐70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. Cytometry Part B Clinical Cytometry. 70B(4). 218–226. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kamruz Darabi Breakdown of academic impact, for papers by Oscar Muñoz Breakdown of academic impact, for papers by Roelof Flierman Breakdown of academic impact, for papers by Luis Gerardo Rodríguez‐Lobato Breakdown of academic impact, for papers by Kazuhiro Mochizuki Breakdown of academic impact, for papers by Zsofia Bittner Breakdown of academic impact, for papers by Maria Velegraki Breakdown of academic impact, for papers by Roseanna Hargreaves Breakdown of academic impact, for papers by Rita I Azevedo Breakdown of academic impact, for papers by Rafael Andreu
Rankless by CCL
2026